Page 1

June 1 , 2021 CORBUS PHARMACEUTICALS Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases • Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFẞ • High potency anti - avẞ8 mAb licensed from University of California San Francisco and anti - avẞ6 / avẞ8 mAb licensed from Panorama Research Inc. • Both mAbs expected to start Phase 1 testing in 2022 • Capital and resources in place to advance multiple programs into clinical development • Company to host conference call and webcast today , Tuesday , June 1 , 2021 at 8:30 a.m. ET Norwood , MA , June 01 , 2021 ( GLOBE NEWSWIRE ) -- Corbus Pharmaceuticals Holdings , Inc. ( NASDAQ : CRBP ) ( " Corbus " or the " Company " ) , today announced licensing deals for two new monoclonal antibodies ( mAbs ) , CRB - 601 and CRB - 602 , that target integrins to inhibit activation of transforming growth factor ẞ ( TGFB ) . This new integrin program , in addition to the existing endocannabinoid system program , strengthens and diversifies Corbus ' immunology pipeline for inflammatory , fibrotic , and metabolic diseases , and cancer . With these additions , Corbus expects to have four compounds other than lenabasum in Phase 1 testing in 2022 . Targeting integrins to inhibit TGFẞ activation TGFB is a multifunctional cytokine involved in many cellular processes , including cell growth and differentiation , immune responses , wound healing , and tissue repair . TGFẞ plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment ( TME ) . The integrins avẞ6 and avẞ8 are expressed by cancer cells , and avẞ6 is also expressed on epithelial cells in fibrotic diseases . These integrins enable TGFß to exert its biologic effects by releasing it from its latent complex . The goal of blocking these integrins is to inhibit the deleterious effects of TGFẞ . A number of other preclinical and early clinical stage programs are testing this approach of inhibiting av integrins . CRB - 601 and CRB - 602 are two novel and distinct anti - integrin mAbs :